Literature DB >> 19714863

How to make siRNA lipoplexes efficient? Add a DNA cargo.

Hervé Rhinn1, Céline Largeau, Pascal Bigey, René Lai Kuen, Magali Richard, Daniel Scherman, Virginie Escriou.   

Abstract

BACKGROUND: We recently reported an efficient formulation of siRNA targeting TNF-alpha, that was able to restore immunological balance in a mouse arthritis model following intravenous injection.
METHOD: Since this efficient formulation included the pre association of siRNA with a DNA cargo, we decided to extensively characterise siRNA lipoplexes with or without DNA cargo, in order to better understand the DNA cargo enhancing effect.
RESULTS: We showed that addition of DNA cargo to siRNA lipoplexes led to specific gene extinction in vitro, using reduced siRNA concentration. This procedure is also applicable to other lipid vectors, like Lipofectamine or DMRIE-C. No structural modification could be observed in siRNA lipoplexes upon addition of DNA cargo using dynamic light scattering or transmission electronic microscopy. Nevertheless, we observed some slight differences, in the amount of lipid required to obtain neutrality of the complex and in stability of the complex towards incubation with heparan sulfate.
CONCLUSIONS: These results suggest that the addition of DNA cargo to siRNA complexes is an easy procedure that leads to more efficient complexes to transfer siRNA at low concentration and in the presence of serum.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19714863     DOI: 10.1016/j.bbagen.2009.01.005

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Essential requirement for β-arrestin2 in mouse intestinal tumors with elevated Wnt signaling.

Authors:  Caroline Bonnans; Maud Flacelière; Fanny Grillet; Christelle Dantec; Jean-Pierre Desvignes; Julie Pannequin; Dany Severac; Emeric Dubois; Frédéric Bibeau; Virginie Escriou; Philippe Crespy; Laurent Journot; Frédéric Hollande; Dominique Joubert
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

2.  Design and evaluation of histidine-rich amphipathic peptides for siRNA delivery.

Authors:  Bérangère Langlet-Bertin; Christian Leborgne; Daniel Scherman; Burkhard Bechinger; A James Mason; Antoine Kichler
Journal:  Pharm Res       Date:  2010-07       Impact factor: 4.200

3.  Nonionic surfactant vesicles for delivery of RNAi therapeutics.

Authors:  Orapan Paecharoenchai; Lesheng Teng; Bryant C Yung; Lirong Teng; Praneet Opanasopit; Robert J Lee
Journal:  Nanomedicine (Lond)       Date:  2013-11       Impact factor: 5.307

Review 4.  Genetic pharmacology: progresses in siRNA delivery and therapeutic applications.

Authors:  D Scherman; A Rousseau; P Bigey; V Escriou
Journal:  Gene Ther       Date:  2017-01-25       Impact factor: 5.250

Review 5.  Lipothioureas as Lipids for Gene Transfection: A Review.

Authors:  Marie Breton; Jeanne Leblond; Isabelle Tranchant; Daniel Scherman; Michel Bessodes; Jean Herscovici; Nathalie Mignet
Journal:  Pharmaceuticals (Basel)       Date:  2011-10-24

6.  Development of dual-activity vectors by co-envelopment of adenovirus and SiRNA in artificial lipid bilayers.

Authors:  Açelya Yilmazer; Bowen Tian; Kostas Kostarelos
Journal:  PLoS One       Date:  2014-12-12       Impact factor: 3.240

7.  Toll-like receptor 2 promiscuity is responsible for the immunostimulatory activity of nucleic acid nanocarriers.

Authors:  Malvina Pizzuto; Monique Gangloff; Daniel Scherman; Nicholas J Gay; Virginie Escriou; Jean-Marie Ruysschaert; Caroline Lonez
Journal:  J Control Release       Date:  2016-12-28       Impact factor: 9.776

Review 8.  Using drug-excipient interactions for siRNA delivery.

Authors:  Katharina Bruno
Journal:  Adv Drug Deliv Rev       Date:  2011-09-17       Impact factor: 15.470

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.